10-Q: ProtoKinetix Faces Going Concern, Boosts Authorized Shares

ProtoKinetix, a development stage biotech, reported increased losses and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern, despite a slight improvement in cash position.

Summary

• ProtoKinetix, a development stage company, continues to research Antifreeze Glycoproteins (AFGP) or anti-aging glycoproteins (AAGP) but has not developed a commercially viable product or generated significant revenue.
• The company reported a net loss of $273,663 for the nine months ended September 30, 2025, an increase from $261,676 for the same period in 2024.
• Cash on hand improved to $607 at September 30, 2025, from a negative balance of $(4,697) at December 31, 2024.
• Working capital deteriorated significantly to $(213,539) at September 30, 2025, from $(127,694) at December 31, 2024.
• Total liabilities increased to $227,196 at September 30, 2025, from $124,047 at December 31, 2024.
• The accumulated deficit grew to $(48,501,809) at September 30, 2025.
• Stockholders approved an amendment to increase the total number of authorized common shares from 500,000,000 to 600,000,000.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to increasing net losses, a worsening working capital position, significant accumulated deficit, and a clear 'going concern' warning. The ineffectiveness of disclosure controls is a major red flag, indicating poor internal governance. While there was a slight improvement in cash balance and reduced cash burn from operations, the overall financial health remains precarious, and reliance on future capital raises is critical and uncertain.

Positives

• Cash position improved from a negative balance of $(4,697) at December 31, 2024, to a positive $607 at September 30, 2025.
• Net cash used in operating activities decreased by $41,873, from $177,808 in 2024 to $135,935 in 2025, primarily due to a change in accounts payable.
• Net cash used in investing activities decreased from $52,910 in 2024 to $36,261 in 2025, reflecting a fluctuation in patent application billings.

Negatives

• Net loss increased to $273,663 for the nine months ended September 30, 2025, compared to $261,676 for the same period in 2024.
• Working capital significantly worsened to a negative $(213,539) at September 30, 2025, from $(127,694) at December 31, 2024.
• Total liabilities increased substantially to $227,196 at September 30, 2025, from $124,047 at December 31, 2024.
• The company has an accumulated deficit of $48,501,809, indicating a history of losses since inception.
• Net cash provided by financing activities decreased by $38,500, from $216,000 in 2024 to $177,500 in 2025, reflecting reduced investor funding.
• Disclosure controls and procedures were concluded to be not effective as of September 30, 2025.

Risks

• The company has not developed a commercially viable product, has not generated any significant revenue, and has incurred losses since inception, raising substantial doubt about its ability to continue as a going concern.
• Continuation of the company as a going concern is dependent upon obtaining additional working capital through equity financing or related party loans.
• Any significant disruption of global financial markets could negatively affect liquidity and ability to continue operations.
• The company's capital requirements and the uncertainty of being able to obtain additional funding on acceptable terms pose a significant risk.
• The company's common stock has a limited trading history, and its price and volume are volatile, which could negatively impact future capital raises.
• The company's disclosure controls and procedures are not effective, which could lead to material misstatements or failures in timely reporting.

Future Outlook

The company is actively seeking additional working capital through equity financing or related party loans to fund its medical research and future business activities. It intends to meet corporate obligations by selling common stock and is pursuing research partners for cost sharing and grants for continued studies on its patented AAGP molecule. No current year marketing projects are planned, and there are no current research projects underway, though molecule storage and consulting fees are being paid.

Management Comments

• "Management is presently engaged in seeking additional working capital through equity financing or related party loans."
• "The Company continues to pursue research partners for cost sharing and engages in institutes with grants available for continued studies on our patented AAGP molecule."
• "We intend to fund the Company and attempt to meet corporate obligations by selling common stock."
• "Our management... concluded that these disclosure controls and procedures are not effective as of September 30, 2025 to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to management... to allow timely decisions regarding required disclosure and are not effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SECs rules and forms."

Industry Context

ProtoKinetix operates as a development-stage biotechnology company, a sector characterized by high R&D costs, long development cycles, and significant reliance on external funding and intellectual property. Its focus on Antifreeze Glycoproteins (AAGP) for anti-aging and healthcare solutions places it in a niche but potentially high-value segment. However, the lack of a commercially viable product and ongoing losses are typical challenges for early-stage biotech firms, but the company's current financial state and ineffective controls suggest a struggle to progress beyond the research phase without substantial external investment or partnerships.

Comparison to Industry Standards

• ProtoKinetix's status as a development-stage company with no revenue and consistent losses is common in early-stage biotechnology, where significant capital is invested in R&D before commercialization.
• The accumulated deficit of over $48 million is substantial for a company without a commercial product, indicating a prolonged period of cash burn, which is higher than many early-stage biotechs that might seek to monetize or partner earlier.
• The negative working capital position of $(213,539) and minimal cash balance of $607 are significantly below industry benchmarks for operational stability, even for development-stage companies, which typically maintain a cash runway of at least 12-18 months.
• The conclusion that disclosure controls and procedures are not effective is a serious governance issue, falling short of the standards expected for publicly traded companies, regardless of size or stage, and is a red flag compared to peers with robust internal controls.
• The reliance on private placements and related party loans for funding, coupled with a decrease in financing cash flow, suggests challenges in attracting broader institutional investment, which is a common hurdle but also a differentiator for successful biotech firms.

Corporate Governance

Related Party Transactions

• A total of $45,000 was paid or accrued to the company's CFO, Michael Guzzetta, pursuant to a consulting agreement.
• The company reimbursed a company controlled by the CFO a total of $4,500 for office rent.
• Balances owing to related parties increased to $105,700 as at September 30, 2025, from $21,500 at September 30, 2024.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk due to ongoing equity financing and the increase in authorized shares. The 'going concern' warning and ineffective disclosure controls pose substantial risks to investment value.
• **Employees/Consultants:** The company's precarious financial position and reliance on future funding could impact job security or payment for services, although some shares were issued for services.
• **Creditors:** Increased accounts payable and accrued liabilities, coupled with the 'going concern' warning, suggest elevated risk regarding the company's ability to meet its short-term obligations.
• **Customers/Partners:** As a development-stage company without a commercial product, there are no direct customer impacts. Potential research partners may be wary given the financial instability and governance issues.

Next Steps

• Management will continue seeking additional working capital through equity financing or related party loans.
• The company plans to pursue research partners for cost sharing and engage with institutes offering grants for continued studies on the AAGP molecule.
• The company intends to fund corporate obligations by selling common stock.
• Management will need to address the ineffectiveness of disclosure controls and procedures.

Key Dates

Recommendation

The company is a development-stage entity with no revenue, a history of increasing losses, and a substantial accumulated deficit, leading to a 'going concern' warning. Its working capital position has significantly deteriorated, and while cash improved slightly, it remains critically low. The explicit declaration of ineffective disclosure controls and procedures is a major governance red flag, indicating a high risk of financial reporting issues. Despite efforts to raise capital and pursue partnerships, the fundamental financial instability and governance weaknesses present an extremely high-risk profile. Investors face significant potential for further capital erosion and should consider exiting their positions.

Keywords

biotechnology, AAGP, Antifreeze Glycoproteins, medical research, development stage, SEC filing, 10-Q, going concern, financial results, liquidity, capital raise, patent application, disclosure controls